VivoSeq
Oncology

Kaposi's Sarcoma

26

Pipeline Programs↗

0

Active Trials↗

28

Companies Involved↗

Kaposi's sarcoma is an emerging landscape with 26 programs across 28 companies. The most active players are EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb, Agouron Pharmaceuticals. 10 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

90/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2A

Agouron Pharmaceuticals

1 program

Phase 2Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

81%

Small molecule

21 of 26 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody415%Gene therapy14%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

60

clinical trials

Completed52 · 87%
Terminated6 · 10%
Unknown status2 · 3%

Clinical Trials

Trial Activity

60 trials

Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000807·41 enrolled
Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma
Completed·RRoswell Park Cancer Institute·Phase 3·NCT00002985
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000996·48 enrolled
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001114·90 enrolled
A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000681·24 enrolled
Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000660·24 enrolled
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
Completed·SSUGEN·Phase 2·NCT00005931·30 enrolled
Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00019123
Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.
Completed·CClinical Solutions·Phase 2·NCT00002167·78 enrolled
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00064142·30 enrolled
A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma
Completed·Roche logoRoche·Phase 2·NCT00002314
Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00295984·24 enrolled
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
Completed·IImmunityBio, Inc.·Phase 2·NCT02029430·15 enrolled
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
Completed·AAIDS Malignancy Consortium·Phase 2·NCT00090987·30 enrolled
Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
Completed·SSUGEN·N/A·NCT00002226·30 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)